Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stelara
Pharma
J&J lifts 2025 sales guidance despite looming tariff threat
Even as tariffs start to impact its medtech business, Johnson & Johnson is lifting its sales guidance for 2025 thanks to a recent neuroscience buyout.
Fraiser Kansteiner
Apr 15, 2025 11:55am
A closer look at pharma’s top patent losses in 2025
Mar 21, 2025 9:00am
J&J's Tremfya picks up key FDA nod in Crohn's disease
Mar 20, 2025 7:56pm
The top 10 drugs losing US exclusivity in 2025
Mar 17, 2025 3:00am
J&J sues Samsung Bioepis over Stelara biosimilar agreement
Feb 25, 2025 10:21am
With biosim sales up 16%, Amgen expects another boost in 2025
Feb 5, 2025 11:28am
